Alle Storys
Folgen
Keine Story von Oxygen Biotherapeutics Inc. mehr verpassen.

Oxygen Biotherapeutics Inc.

EANS-Adhoc: Oxygen Biotherapeutics Reports First Quarter FY2011 Financial Results

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
quarterly report/Biotechnology
10.09.2010
DURHAM, NC, September 9, 2010 — Oxygen Biotherapeutics, Inc. (NASDAQ 
and SIX Swiss Exchange: OXBT), a development stage biomedical company
focused on developing oxygen-rich intravenous and topical products, 
today announced results for the fiscal year (FY) first quarter ended 
July 31, 2010.
Oxygen Biotherapeutics reported a net loss of approximately $3 
million, or $0.13 per share, for the three months ended July 31, 
2010, compared to a net loss of $2.4 million, or $0.15 per share for 
the same period in the prior year. The increase in net loss over the 
same period last year was primarily due to an increase in costs 
associated with our Phase II-b trial for traumatic brain injury, 
market analysis and direct marketing expenses for DERMACYTE 
cosmetics, and an increase in legal and accounting fees for services 
provided for filing registration statements and listing with the 
Swiss SIX Stock Exchange.
The Company reported other income of $27,217 for the quarter, a 28% 
increase over other income of $21,283 for the same period in the 
prior year. The increase in other income was due to online sales of 
our Dermacyte Concentrate skin care product, which began in late 
April.
As of July 31, 2010, the Company had cash and cash equivalents 
totalling $2.8 million, up from $632,706 at April 30, 2010.
"Fiscal year 2011 began with raising approximately $5 million via two
financing vehicles. That capital enabled us to move our clinical and 
preclinical research for Oxycyte forward as well as to ramp up our 
sales and marketing efforts behind our newly introduced DERMACYTE 
cosmetic line," said Chris Stern, Chairman and Chief Executive 
Officer of Oxygen Biotherapeutics. "Much of the work we´ve done 
involves research, planning and behind the scene actions that are 
necessary to drive our programs forward and to build market awareness
for DERMACYTE."
end of ad-hoc-announcement
Corporate Highlights (reflect activities from April 30 – September 8, 2010)
Clinical & Preclinical Update
•In May, we entered into an agreement with a site monitoring company 
to expand our Phase II-b clinical trial for traumatic brain injury 
into India. In September, we were informed that Israeli soldiers who 
suffer severe traumatic brain injury (TBI) can be enrolled in the 
company’s TBI trials at clinical sites in Israel.
•Preclinical studies from the University of Miami showed that Oxycyte
improves the volume of preserved neuronal tissue in the spinal cord 
following injury. Researchers saw a favorable improvement in 
functional recovery as assessed by footprint analysis six weeks post 
treatment.
•Results from U.S. Navy preclinical studies demonstrated decreased 
mortality in porcine animal models that were given an intravenous 
dose of Oxycyte after the onset of decompression sickness (DCS). 
These results showed a statistically significant decrease in 
mortality compared with the control group that did not receive 
Oxycyte. This data was published in the June issue of Aviation Space 
and Environmental Medicine.
•Entered into a Cooperative Research and Development Agreement with 
the U.S. Naval Medical Research Center to conduct preclinical trials 
to assess the safety and efficacy of Oxycyte perfluorocarbon emulsion
for the prevention and treatment of decompression sickness and 
related injuries.
Dermacyte Update
•Launched two skin care products, DERMACYTE Oxygen Concentrate and 
DERMACYTE Oxygenating Eye Complex.  Both products are now available 
in elegant pump bottles on-line at www.buydermacyte.com. Sales 
activities to place products in spas and resorts are underway.
•DERMACYTE cosmetic study conducted with 36 women ages 39-63 with 
mild-to-moderate facial wrinkles reported that 80% of subjects 
experienced at least one-grade improvement on the Fitzpatrick Wrinkle
Assessment Scale (FWAS) (P<0.0001); 97% experienced at least one 
grade of improvement compared to their baseline photos according to 
the investigator's Global Improvement Aesthetic Scale (GIAS) 
(P<0.0001); and 84% has at least a grade of improvement on their 
self-perception of GIAS (P<0.0001).
•Developed the first phase of our internal sales force targeting spas
and dermatologists in New York, Michigan and Arizona.
•Promotional marketing efforts underway include public relations to 
secure coverage in general, trade and online publications, trade 
advertising, tradeshow exhibiting, promotional material development, 
a new product web site and product promotions through events, 
e-zines, beauty magazines and blogs.
•Ongoing efforts to secure a partnership with a major cosmetic 
company with the objective of placing our oxygen-rich products in 
retail outlets.
Corporate Update
•Raised nearly $5 in capital from a registered direct offering and 
from the Vatea Fund.
•In June, shares of OXBT common stock began trading on the Swiss SIX 
Stock Exchange.
•In June, our Company was included in the Russell Microcap Index 
which measures the performance of the microcap segment of the U.S. 
equity market.
About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is 
developing medical and cosmetic products that efficiently deliver 
oxygen to tissues in the body. The Company has developed a 
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and 
liquid ventilation product called Oxycyte® that is being formulated 
for both intravenous and topical delivery for conditions including 
but not limited to traumatic brain injury, decompression sickness and
topical wounds.  This same PFC is included in the Company’s full line
of personal skin care products. More information is available at 
www.oxybiomed.com.
Caution Regarding Forward-Looking Statements This news release 
contains certain forward-looking statements by the company that 
involve risks and uncertainties and reflect the company's judgment as
of the date of this release. These statements include the expansion 
of development of the Oxycyte and DERMACYTE product lines and the 
timing of the introduction of those new products. The forward-looking
statements are subject to a number of risks and uncertainties 
including matters beyond the company's control that could lead to 
delays in new product introductions and customer acceptance of these 
new products, and other risks and uncertainties as described in our 
filings with the Securities and Exchange Commission, including in the
current reports on Form 10-Q and Form-10K. The company disclaims any 
intent or obligation to update these forward-looking statements 
beyond the date of this release. This caution is made under the safe 
harbor provisions of the Private Securities Litigation Reform Act of 
1995.
end of announcement                               euro adhoc

Further inquiry note:

Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
2530 Meridian Pkwy, 3rd floor
Durham, NC 27713
Direct Telephone: +1 919 855 2112
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: 10728277
Index: SSIRT
Börsen: New York / Nasdaq
SIX Swiss Exchange / Main Standard

Weitere Storys: Oxygen Biotherapeutics Inc.
Weitere Storys: Oxygen Biotherapeutics Inc.